- Trials with a EudraCT protocol (120)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
120 result(s) found for: Capsule endoscopy.
Displaying page 4 of 6.
EudraCT Number: 2006-005377-22 | Sponsor Protocol Number: BUC-57/UCA | Start Date*: 2007-10-23 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with 9 mg budesonide or 3 g mesalazine in pat... | |||||||||||||
Medical condition: Treatment of ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Completed) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011608-51 | Sponsor Protocol Number: MCA111407 | Start Date*: 2009-08-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients wit... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001188-70 | Sponsor Protocol Number: T-EE04-085 | Start Date*: 2006-03-06 |
Sponsor Name:TAP Pharmaceutical Products Inc. | ||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis | ||
Medical condition: Erosive esophagitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) LV (Completed) LT (Completed) CZ (Completed) HU (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003113-34 | Sponsor Protocol Number: CLYS006X2202 | Start Date*: 2020-02-19 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, multi-center, subject and investigator blinded, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of LYS006 in patients with mild to moderate ul... | ||||||||||||||||||
Medical condition: Mild to moderate ulcerative colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001600-64 | Sponsor Protocol Number: RPC01-3102 | Start Date*: 2015-10-14 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Completed) GB (Completed) SK (Completed) HU (Trial now transitioned) BG (Trial now transitioned) NL (Completed) BE (Trial now transitioned) HR (Completed) LV (Completed) AT (Prematurely Ended) GR (Completed) ES (Prematurely Ended) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006957-42 | Sponsor Protocol Number: BUG-2/CDA | Start Date*: 2009-10-30 | ||||||||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | ||||||||||||||||||
Full Title: Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide th... | ||||||||||||||||||
Medical condition: Induction of remission in active Crohn´s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) LT (Completed) BG (Completed) CZ (Completed) LV (Completed) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004610-27 | Sponsor Protocol Number: CR-IBD-1-08 | Start Date*: 2008-12-02 | |||||||||||
Sponsor Name:Palau Pharma S.A. | |||||||||||||
Full Title: A double-blind, randomised, placebo and mesalazine controlled phase II study to explore the safety and activity of dersalazine in patients with mild to moderate active colitis | |||||||||||||
Medical condition: Mild to moderate active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003208-19 | Sponsor Protocol Number: GWID10160 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:GW Pharma Ltd. | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis. | |||||||||||||
Medical condition: Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003199-11 | Sponsor Protocol Number: 2013-1 | Start Date*: 2015-09-25 |
Sponsor Name:GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives | ||
Full Title: Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study. | ||
Medical condition: Crohn's disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004132-20 | Sponsor Protocol Number: D9423C00001 | Start Date*: 2016-07-28 | |||||||||||
Sponsor Name:AstraZeneca K.K. | |||||||||||||
Full Title: A multicentre, double-blind, randomised, parallel-group, Phase III study to assess efficacy and safety of D9421-C 9 mg versus Mesalazine 3 g in patients with active Crohn’s Disease in Japan | |||||||||||||
Medical condition: Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002779-42 | Sponsor Protocol Number: BY359/M3-201 | Start Date*: 2006-11-06 | |||||||||||
Sponsor Name:ALTANA Pharma AG | |||||||||||||
Full Title: Symptom relief and tolerability of Soraprazan 20 mg qd and Soraprazan 10 mg qd compared to Esomeprazole 20 mg qd in patients with non-erosive gastroesophageal reflux disease (NERD) | |||||||||||||
Medical condition: Non-Erosive Gastroesophageal Reflux Disease (NERD) as confirmed by endoscopy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001148-22 | Sponsor Protocol Number: CRAD001F2201 | Start Date*: 2005-06-27 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005203-32 | Sponsor Protocol Number: NERONE | Start Date*: 2012-04-17 | |||||||||||
Sponsor Name:UNIVERSITA' CAMPUS BIOMEDICO | |||||||||||||
Full Title: A prospective, multicenter, open-label, patients with non-erosive gastroesophageal reflux disease (NERD) non-responders to therapy with PPIs | |||||||||||||
Medical condition: non-erosive gastroesophageal reflux disease and apparently resistant to medical therapy with proton pump inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005455-42 | Sponsor Protocol Number: IBD-ENDO-2008-1 | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: ENDO ACE TRIAL Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk; a randomized controlled tri... | |||||||||||||
Medical condition: Crohn's disease. Patients with Crohn's disease with status after ileocecal resection. Stenotic ileocecal anastomosis with symptoms of obstruction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001022-42 | Sponsor Protocol Number: IBD98-M-2002 | Start Date*: 2015-12-01 | |||||||||||
Sponsor Name:Holy Stone Healthcare Co., Ltd. | |||||||||||||
Full Title: A Phase 2a, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients with Active, Mild to Moderate Ulcerat... | |||||||||||||
Medical condition: Active, Mild to Moderate Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004096-36 | Sponsor Protocol Number: THALI-HHT | Start Date*: 2011-10-11 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) | |||||||||||||
Medical condition: Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002702-51 | Sponsor Protocol Number: 010951201207 | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:Department of medical gastroenterology S, Odense University Hospital | |||||||||||||
Full Title: Discontinuation of infliximab therapy in patients with Crohn’s disease during sustained complete remission: A Nordic multi-center, double blinded, randomized, placebo controlled study | |||||||||||||
Medical condition: Patients with Crohn's disease with absence of disease activity during biologic therapy (infliximab) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005999-18 | Sponsor Protocol Number: PI20/01514 | Start Date*: 2022-06-24 | |||||||||||
Sponsor Name:Instituto de Investigación Sanitaria Aragón | |||||||||||||
Full Title: Effect of obesity on COX1 and 2 acetylation by aspirin as a biomarker of its efficacy in colon cancer chemoprevention and therapy. | |||||||||||||
Medical condition: Colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004032-19 | Sponsor Protocol Number: NLOCEAN.505.14 | Start Date*: 2015-09-09 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal... | ||
Medical condition: small bowel angiodysplasias | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003307-21 | Sponsor Protocol Number: 848016005-02 | Start Date*: 2018-05-30 |
Sponsor Name:Maastricht University | ||
Full Title: Tailored treatment of functional dyspepsia with nortriptyline: a multi-center double-blind placebo-controlled trial (TENDER) | ||
Medical condition: Functional dyspepsia (FD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
